natgillin/translations-raw huggingface dataset:
In clinical trials including 1,723 patients treated with imipenem/cilastatin intravenous the most frequently reported systemic adverse reactions that were reported at least possibly related to therapy were nausea (2.0%), diarrhoea (1.8%), vomiting (1.5%), rash (0.9%), fever (0.5%), hypotension (0.4%), seizures (0.4%) (see section 4.4), dizziness (0.3%), pruritus (0.3%), urticaria (0.2%), somnolence (0.2%).
V kliničnih preskušanjih pri 1.723 bolnikih, intravensko zdravljenih z imipenemom/cilastatinom, so bili najpogosteje poročani sistemski neželeni učinki, navedeni kot vsaj možno povezani z zdravljenjem, navzea (2,0%), driska (1,8%), bruhanje (1,5%), izpuščaj (0,9%), zvišana telesna temperatura (0,5%), hipotenzija (0,4%), napadi krčev (0,4%) (glejte poglavje 4.4), omotica (0,3%), srbenje (0,3%), urtikarija (0,2%) in zaspanost (0,2%).
Take special care with TIENAM
Bodite posebno pozorni pri jemanju zdravila TIENAM
Very rare cyanosis, tachycardia, palpitations
Zelo redki cianoza, tahikardija, palpitacije
Animal studies showed that the toxicity produced by imipenem, as a single entity, was limited to the kidney.
Študije na živalih so pokazale, da so toksični učinki imipenema, uporabljenega samega, omejeni na ledvice.
Due to the limited extent of hepatic metabolism of imipenem, its pharmacokinetics are not expected to be affected by hepatic impairment.
Zaradi majhnega obsega presnove imipenema v jetrih ni pričakovati, da bi okvara jeter vplivala na njegovo farmakokinetiko.
As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.
Če je lokalna prevalenca odpornosti takšna, da je uporabnost tega zdravila vsaj pri nekaterih vrstah okužb vprašljiva, je treba poiskati nasvet strokovnjaka.
There are some side effects associated with this product (such as seeing, hearing, or feeling something that is not there, dizziness, sleepiness, and a spinning sensation) that may affect some patients' ability to drive or operate machinery (see section 4).
S tem zdravilom je povezanih nekaj neželenih učinkov (kot so videnje, slišanje ali občutenje stvari, ki jih ni, omotica, zaspanost in vrtoglavica), ki lahko pri nekaterih bolnikih poslabšajo njihovo sposobnost upravljanja vozil in strojev (glejte poglavje 4).
• Imipenem is stable to hydrolysis by most beta-lactamases, including penicillinases and cephalosporinases produced by gram-positive and gram-negative bacteria, with the exception of relatively rare carbapenem hydrolysing beta-lactamases.
Imipenem je stabilen proti hidrolizi z večino betalaktamaz, vključno s penicilinazami in cefalosporinazami, ki jih tvorijo grampozitivne in gramnegativne bakterije, z izjemo razmeroma redkih betalaktamaz, ki hidrolizirajo karbapeneme.
The usual dose for children one year of age or older is 15/15 or 25/25 mg/kg/dose every 6 hours.
Običajen odmerek za otroke, stare eno leto ali več, je 15/15 ali 25/25 mg/kg/odmerek na vsakih 6 ur.
Patients with a creatinine clearance of ≤5 ml/min/1.73 m2
Bolniki z očistkom kreatinina ≤5 ml/min/1,73 m2
Cilastatin is a specific inhibitor of dehydropeptidase-I enzyme and effectively inhibits metabolism of imipenem so that concomitant administration of imipenem and cilastatin allows therapeutic antibacterial levels of imipenem to be attained in both urine and plasma.
Cilastatin je specifičen zaviralec encima dehidropeptidaze-I in učinkovito zavre presnovo imipenema; sočasna uporaba imipenema in cilastatina tako omogoča, da imipenem doseže terapevtsko protibakterijsko koncentracijo v urinu in plazmi.
Very rare aggravation of myasthenia gravis, headache
Zelo redki poslabšanje miastenije gravis, glavobol
Very rare vertigo, tinnitus
Zelo redki vrtoglavica, tinitus
It is important to consider this diagnosis in patients who develop diarrhoea during or after the use of imipenem/cilastatin (see section 4.8).
Na to diagnozo je treba pomisliti pri vseh bolnikih, ki med uporabo imipenema/cilastatina ali po njej dobijo drisko (glejte poglavje 4.8).
A teratology study in pregnant cynomolgus monkeys given imipenem-cilastatin sodium at doses of 40/40 mg/kg/day (bolus intravenous injection) resulted in maternal toxicity including emesis, inappetence, body weight loss, diarrhoea, abortion, and death in some cases.
V teratološki študiji pri nosečih opicah cynomolgus, ki so dobivale imipenem/natrijevo sol cilastatina v odmerkih 40/40 mg/kg/dan (bolusna intravenska injekcija), so se pojavili toksični učinki pri materah; obsegali so bruhanje, pomanjkanje apetita, hujšanje, drisko, splav in v nekaterih primerih smrt.
Co-administration of cilastatin with imipenem in a 1:1 ratio prevented the nephrotoxic effects of imipenem in rabbits and monkeys.
Sočasna uporaba cilastatina in imipenema v razmerju 1:1 je pri kuncih in opicah preprečila nefrotoksične učinke imipenema.
Mode of action TIENAM consists of two components: imipenem and cilastatin sodium in a 1:1 ratio by weight.
Način delovanja Zdravilo TIENAM vsebuje dve učinkovini: imipenem in natrijevo sol cilastatina v razmerju mase 1:1.
Greece: Primaxin
Grčija: Primaxin
Central nervous system
Osrednje živčevje
The remainder of the administered dose was recovered in the urine as antibacterially inactive metabolites, and faecal elimination of imipenem was essentially nil.
Preostanek uporabljenega odmerka se je pojavil v urinu v obliki protibakterijsko neaktivnih presnovkov, odstranjevanja imipenema v blatu pa praktično ni.
Each dose of 500 mg/500 mg should be given by intravenous infusion over 20 to 30 minutes.
Vsak odmerek 500 mg/500 mg je treba dati v intravenski infuziji v obdobju 20 do 30 minut.
In healthy elderly volunteers (65 to 75 years of age with normal renal function for their age), the pharmacokinetics of a single dose of TIENAM 500 mg/500 mg administered intravenously over 20 minutes were consistent with those expected in subjects with slight renal impairment for which no dose alteration is considered necessary.
Pri zdravih starejših prostovoljcih (starih od 65 do 75 let in z normalnim delovanjem ledvic za njihovo starost) se farmakokinetika enkratnega odmerka zdravila TIENAM 500 mg/500 mg, danega intravensko v 20 minutah, sklada s farmakokinetiko oseb z rahlo okvaro ledvic, pri katerih prilagoditev odmerka ni potrebna.
500 mg/500 mg every 6 hours OR 1000 mg/1000 mg every 8 hours OR every 6 hours
500 mg/500 mg vsakih 6 ur ALI 1.000 mg/1.000 mg vsakih 8 ur ALI vsakih 6 ur.
Before initiating therapy with TIENAM, careful inquiry should be made concerning previous hypersensitivity reactions to carbapenems, penicillins, cephalosporins, other beta-lactams and other allergens (see section 4.3).
Pred uvedbo zdravljenja z zdravilom TIENAM je treba natančno poizvedeti, ali je bolnik kdaj v preteklosti imel preobčutljivostno reakcijo na karbapeneme, peniciline, cefalosporine, druge betalaktamske antibiotike ali druge alergene (glejte poglavje 4.3).
Very rare gastro-enteritis
Zelo redki gastroenteritis
The concomitant use of imipenem/cilastatin and valproic acid/sodium valproate is not recommended (see section 4.5).
Sočasna uporaba imipenema/cilastatina in valprojske kisline oz. natrijevega valproata ni priporočljiva (glejte poglavje 4.5).
Rare anaphylactic reactions
Redki anafilaktične reakcije
• Infection affecting the lungs (pneumonia)
• okužbo pljuč (pljučnico)
Rare agranulocytosis
Redki agranulocitoza
Commonly susceptible species: Gram-positive aerobes: Enterococcus faecalis Staphylococcus aureus (Methicillin-susceptible)*
Pogosto občutljive vrste: Grampozitivni aerobi: Enterococcus faecalis Staphylococcus aureus (občutljiv za meticilin)*
3 Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.
3 Sklepanje o občutljivosti stafilokokov za karbapeneme temelji na občutljivosti za cefoksitin.
Contents of each vial must be transferred to 100 ml of an appropriate infusion solution (see Incompatibility and After reconstitution): 0.9% sodium chloride.
Vsebino ene viale je treba prenesti v 100 ml ustrezne raztopine za infundiranje (glejte: Inkompatibilnost in Po pripravi): 0,9 % raztopino natrijevega klorida.
The lowered valproic acid levels can lead to inadequate seizure control; therefore, concomitant use of imipenem and valproic acid/sodium valproate is not recommended and alternative antibacterial or anti-convulsant therapies should be considered (see section 4.4).
Zmanjšanje koncentracije valprojske kisline lahko povzroči neustrezno obvladanje napadov krčev, zato sočasna uporaba imipenema in valprojske kisline oz. natrijevega valproata ni priporočljiva in je treba razmisliti, če ne bi uporabili drugih protibakterijskih ali antiepileptičnih zdravil (glejte poglavje 4.4).
* A further proportionate reduction in dose administered must be made for patients with a body weight
* Dodatno sorazmerno zmanjšanje uporabljenega odmerka je potrebno pri bolnikih s telesno maso < 70 kg.
Imipenem, also referred to as N-formimidoyl-thienamycin, is a semi-synthetic derivative of thienamycin, the parent compound produced by the filamentous bacterium Streptomyces cattleya.
Imipenem (N-formimidoil-tienamicin) je pol-sintezni derivat tienamicina, matične spojine, ki jo izdeluje filamentozna bakterija Streptomyces cattleya.
It is recommended that infections suspected or proven to be due to less susceptible bacterial species (such as Pseudomonas aeruginosa) and very severe infections (e.g. in neutropenic patients with a fever) should be treated with 25/25 mg/kg administered every 6 hours.
Priporočeno je, da se pri okužbah, za katere obstaja sum oz. za katere je dokazano, da jih povzročajo manj občutljive vrste bakterij (kot je Pseudomonas aeruginosa), in zelo hudih okužbah (npr. pri nevtropeničnih bolnikih z zvišano telesno temperaturo) bolnike zdravi z odmerki 25/25 mg/kg vsakih 6 ur.
The dose recommendations for TIENAM represent the quantity of imipenem/cilastatin to be administered.
Priporočila za odmerjanje zdravila TIENAM pomenijo količino imipenema/cilastatina, ki jo je treba uporabiti.
If CNS symptoms continue, the dose of TIENAM should be decreased or discontinued.
Če se simptomi s strani osrednjega živčevja nadaljujejo, je treba odmerek zdravila TIENAM zmanjšati ali uporabo zdravila prekiniti.
Non-clinical data reveal no special hazard for humans based on repeated dose toxicity and genotoxicity studies.
Predklinični podatki na osnovi študij toksičnosti pri ponavljajočih se odmerkih in genotoksičnosti ne kažejo posebnega tveganja za človeka.
TIENAM is to be reconstituted and further diluted (see section 6.2, 6.3 and 6.6) prior to administration.
Zdravilo TIENAM je treba pred uporabo pripraviti in nato razredčiti (glejte poglavja 6.2, 6.3 in 6.6).
SPECIAL STORAGE CONDITIONS Do not store above 25C
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte pri temperaturi do 25 C.
However, there are some side effects (such as hallucination, dizziness, somnolence, and vertigo) associated with this product that may affect some patients' ability to drive or operate machinery (see section 4.8).
Vendar lahko nekateri neželeni učinki, povezani s tem zdravilom (kot so halucinacije, omotica, zaspanost in vrtoglavica), pri nekaterih bolnikih vplivajo na sposobnost vožnje in upravljanja s stroji (glejte poglavje 4.8).
• Complicated skin and soft tissue infections
• zapleteno okužbo kože in mehkih tkiv
Multiple dosing has no effect on the pharmacokinetics of either imipenem or cilastatin, and no accumulation of imipenem/cilastatin was observed (see section 4.2).
Večkratno odmerjanje ne vpliva ne na farmakokinetiko imipenema ne na farmakokinetiko cilastatina in kopičenja imipenema/cilastatina niso opazili (glejte poglavje 4.2).
TIENAM and associated names (see Annex I) 500 mg/500 mg powder for solution for infusion [See Annex I - To be completed nationally]
TIENAM in z njim povezana imena (glejte Dodatek I) 500 mg/500 mg prašek za raztopino za infundiranje [Glejte Dodatek I - izpolni država članica]
For patients with normal renal function (creatinine clearance of >70 ml/min/1.73 m2), the recommended dose regimens are:
Za bolnike z normalnim delovanjem ledvic (očistek kreatinina > 70 ml/min/1,73 m2) so priporočene sheme odmerjanja:
Common diarrhoea, vomiting, nausea Medicinal product-related nausea and/or vomiting appear to occur more frequently in granulocytopenic patients than in nongranulocytopenic patients treated with TIENAM
Pogosti driska, bruhanje, navzea Kaže, da se z zdravilom povezana navzea in/ali bruhanje med zdravljenjem z zdravilom TIENAM pogosteje pojavita pri granulopeničnih kot pri negranulopeničnih bolnikih.
Hence close adherence to recommended dose schedules is urged especially in these patients (see section 4.2).
Zato je treba še zlasti pri teh bolnikih natančno upoštevati priporočene razporede odmerkov (glejte poglavje 4.2).
Therefore, your doctor will decide whether you should use TIENAM while breast-feeding.
Zato bo zdravnik presodil, ali naj med obdobjem dojenja prejemate zdravilo TIENAM.
Clinical data are insufficient to recommend dosing for paediatric patients with renal impairment (serum creatinine > 2 mg/dl).
Kliničnih podatkov ni dovolj, da bi bilo mogoče priporočiti odmerjanje za otroke z okvaro ledvic (kreatinin v serumu > 2 mg/dl).
TIENAM should not be used during pregnancy unless your doctor decides the potential benefit justifies the potential risk to the foetus.
Zdravila TIENAM se med nosečnostjo ne sme uporabljati, razen če zdravnik presodi, da možna korist upravičuje možno tveganje za plod.
TIENAM may be used in the management of patients with low white blood cell counts, who have fever that is suspected to be due to a bacterial infection.
Zdravilo TIENAM se lahko uporablja za zdravljenje bolnikov, ki imajo majhno število belih krvnih celic in zvišano telesno temperaturo, za katero sumimo, da je posledica bakterijske okužbe.
Cilastatin sodium is a competitive, reversible and specific inhibitor of dehydropeptidase-I, the renal enzyme which metabolizes and inactivates imipenem.
Natrijeva sol cilastatina je kompetitiven, reverzibilen in specifičen zaviralec dehidropeptidaze-I, ledvičnega encima, ki presnovi in inaktivira imipenem.
For paediatric patients ≥1 year of age, the recommended dose is 15/15 or 25/25 mg/kg/dose administered every 6 hours.
Za pediatrične bolnike, stare ≥1 leto, je priporočeni odmerek 15/15 ali 25/25 mg/kg/odmerek, uporabljen na 6 ur.
Each dose >500 mg/500 mg should be infused over 40 to 60 minutes.
Vsak odmerek > 500 mg/500 mg je treba infundirati v obdobju od 40 do 60 minut.
It is recommended that infections suspected or proven to be due to less susceptible bacterial species (such as Pseudomonas aeruginosa) and very severe infections (e.g. in neutropenic patients with a fever) should be treated with 1000 mg/1000 mg administered every 6 hours.
Priporočeno je, da se pri okužbah, za katere obstaja sum oz. za katere je dokazano, da jih povzročajo manj občutljive vrste bakterij (kot je Pseudomonas aeruginosa), in zelo hudih okužbah (npr. pri nevtropeničnih bolnikih z zvišano telesno temperaturo) bolnike zdravi z odmerki 1.000 mg/1.000 mg vsakih 6 ur.
The average clearance (CL) and volume of distribution (Vdss) for imipenem were approximately 45% higher in paediatric patients (3 months to 14 years) as compared to adults.
Pri pediatričnih bolnikih (starih od 3 mesece do 14 let) sta bila povprečni očistek (CL) in volumen porazdelitve (Vdss) imipenema pribilžno 45% večja kot pri odraslih.
Ureoplasma urealyticum * All methicillin-resistant staphylococci are resistant to imipenem/cilastatin.
Ureoplasma urealyticum *Vsi proti meticilinu odporni stafilokoki so odporni tudi proti imipenemu/cilastatinu.
When treating patients with creatinine clearances of 5 ml/min/1.73 m2 who are undergoing dialysis use the dose recommendation for patients with creatinine clearances of 6 to 20 ml/min/1.73 m2 (see table 1).
Za zdravljenje bolnikov z očistkom kreatinina 5 ml/min/1,73 m2, ki so na dializi, je treba uporabiti priporočeni odmerek za bolnike z očistkom kreatinina 6 do 20 ml/min/1,73 m2 (glejte preglednico 1).
Very rare haemolytic anaemia, bone marrow depression
Zelo redki hemolitična anemija, depresija kostnega mozga
• Streptococcus A, B, C, G: The beta-lactam susceptibility of beta-haemolytic streptococcus groups A,
Streptococcus A, B, C, G: sklepanje o občutljivosti beta-hemolitičnih streptokokov skupin A, B, C in G za betalaktame temelji na občutljivosti za penicilin.
Following a single 250 mg/250 mg intravenous dose of TIENAM given 24 hours after haemodialysis, AUCs for imipenem and cilastatin were 3.7-fold and 16.4-fold higher, respectively, as compared to subjects with normal renal function.
Po enkratnem intravenskem odmerku 250 mg/250 mg zdravila TIENAM, uporabljenem 24 ur po hemodializi, je bila AUC imipenema 3,7-krat večja in AUC cilastatina 16,4-krat večja kot pri osebah z normalnim delovanjem ledvic.
Species resistant to other carbapenems do generally express co-resistance to imipenem.
Vrste, odporne proti drugim karbapenemom, so praviloma odporne tudi proti imipenemu.
If you are concerned that you may have been given too much TIENAM, contact your doctor or another healthcare professional immediately.
Če vas skrbi, da ste dobili preveč zdravila TIENAM, to nemudoma povejte zdravniku ali drugemu zdravstvenemu delavcu.
TIENAM should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Zdravilo TIENAM naj bi med nosečnostjo uporabili le, če možna korist upravičujejo možno tveganje za plod.
Rare encephalopathy, paraesthesia, focal tremor, taste perversion
Redki encefalopatija, parestezije, fokalni tremor, motnje okušanja
The usual dose of TIENAM for adults and adolescents is 500 mg/500 mg every 6 hours or 1,000 mg/1,000 mg every 6 or 8 hours.
Običajen odmerek zdravila TIENAM za odrasle in mladostnike je 500 mg/500 mg na vsakih 6 ur ali 1.000 mg/1.000 mg na vsakih 6 ali 8 ur.
Symptoms of overdose may include seizures, confusion, tremors, nausea, vomiting, low blood pressure and slow heart rate.
Če ste uporabili večji odmerek zdravila TIENAM, kot bi smeli Simptomi prevelikega odmerjanja lahko vključujejo napade krčev, zmedenost, tresenje, siljenje na bruhanje, bruhanje, nizek krvni tlak in počasen srčni utrip.
• Severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other type of beta lactam antibacterial agent (e.g. penicillins or cephalosporins).
Huda preobčutljivost (npr. anafilaktična reakcija, huda kožna reakcija) za katerokoli drugo betalaktamsko protibakterijsko zdravilo (npr. za peniciline ali cefalosporine).
For patients on haemodialysis, TIENAM is recommended only when the benefit outweighs the potential risk of seizures (see section 4.2).
Za bolnike na hemodializi je zdravilo TIENAM priporočljivo le, če korist odtehta možno tveganje za napade krčev (glejte poglavje 4.2).
Very rare haemorrhagic colitis, abdominal pain, heartburn, glossitis, tongue papilla hypertrophy, increased salivation
Zelo redki hemoragični kolitis, bolečine v trebuhu, zgaga, glositis, hipertrofija papil na jeziku, močnejše slinjenje
Uncommon seizures, myoclonic activity, dizziness, somnolence
Občasni napadi krčev, mioklonična aktivnost, omotica, zaspanost
Children TIENAM is not recommended in children less than one year of age or children with kidney problems.
Uporabe zdravila TIENAM ne priporočamo pri otrocih, mlajših od enega leta starosti, in pri otrocih z ledvičnimi težavami.
If you are concerned that you may have missed a dose, contact your doctor or another healthcare professional immediately.
Če vas skrbi, da niste dobili odmerka zdravila, to nemudoma povejte zdravniku ali drugemu zdravstvenemu delavcu.
Uncommon fever, local pain and induration at the injection site, erythema at the injection site
Občasni zvišana telesna temperatura, lokalne bolečine in zatrdlina na mestu injiciranja, eritem na mestu injiciranja
• Hypersensitivity to the active substances or to any of the excipients
Preobčutljivost za zdravilni učinkovini ali katero od pomožnih snovi.
The following information is intended for medical or healthcare professionals only: Each vial is for single use only.
Naslednje informacije so namenjene samo zdravstvenemu osebju:
The following adverse reactions have been reported in clinical studies or during post-marketing experience.
V kliničnih študijah in v obdobju trženja zdravila so poročali o naslednjih neželenih učinkih.
Following a single 250 mg/250 mg intravenous dose of TIENAM, the area under the curve (AUCs) for imipenem increased 1.1-fold, 1.9-fold, and 2.7-fold in subjects with mild (Creatinine Clearance (CrCL) 50-80 ml/min/1.73 m2), moderate (CrCL 30-<50 ml/min/1.73 m2), and severe (CrCL <30 ml/min/1.73 m2) renal impairment, respectively, compared to subjects with normal renal function (CrCL >80 ml/min/1.73 m2), and AUCs for cilastatin increased 1.6-fold, 2.0-fold, and 6.2-fold in subjects with mild, moderate, and severe renal impairment, respectively, compared to subjects with normal renal function.
Po enkratnem intravenskem odmerku 250 mg/250 mg zdravila TIENAM je bila površina pod krivuljo (AUC) imipenema pri bolnikih blago okvaro ledvic (očistek kreatinina (CrCL) 50-80 ml/min/1,73 m2) 1,1-krat večja, z zmerno okvaro ledvic (CrCL 30-<50 ml/min/1,73 m2) 1,9-krat večja in s hudo okvaro ledvic (CrCL <30 ml/min/1,73 m2) 2,7-krat večja kot pri osebah z normalnim delovanjem ledvic (CrCL >80 ml/min/1,73 m2).
Very rare chest discomfort, asthenia/weakness
Zelo redki nelagodje v prsih, astenija/šibkost
Imipenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs).
Imipenem deluje baktericidno z zavrtjem sinteze bakterijske celične stene grampozitivnih in gramnegativnih bakterij z vezavo na penicilin vežoče beljakovine.
Do not store above 25 C.
Shranjujte pri temperaturi do 25C.
Urinary recovery, renal clearance and plasma clearance of imipenem and cilastatin decrease with decreasing renal function following intravenous administration of TIENAM.
Pojavljanje imipenema in cilastatina v urinu, njun ledvični očistek in plazemski očistek se po intravenski uporabi zdravila TIENAM z zmanjševanjem delovanja ledvic zmanjšujejo.
It is important that you tell your doctor if you are breast-feeding or if you intend to breast-feed before receiving TIENAM.
Pomembno je, da zdravniku poveste, če dojite ali če nameravate dojiti, preden dobite zdravilo TIENAM.
Paediatric population with renal impairment
Pediatrični bolniki z okvaro ledvic
TIENAM is given intravenously (into a vein) over 20-30 minutes for a dose of ≤500 mg/500 mg or 40-60 minutes for a does of >500 mg/500 mg.
Zdravilo TIENAM se daje intravensko (v veno), in sicer v 20 do 30 minutah pri odmerkih ≤ 500 mg/500 mg in v 40-60 minutah pri odmerkih > 500 mg/500 mg.
Concomitant administration of TIENAM and probenecid resulted in minimal increases in the plasma levels and plasma half-life of imipenem.
Pri sočasni uporabi zdravila TIENAM in probenecida sta se koncentracija in razpolovni čas imipenema v plazmi minimalno povečala.
Intravenous use after reconstitution.
intravenska uporaba po pripravi samo za enkratno uporabo
Each vial contains sodium bicarbonate equivalent to approximately 1.6 mEq of sodium (approximately 37.6 mg).
Ena viala vsebuje približno 1,6 mEq natrija v obliki natrijevega hidrogenkarbonata (približno 37,6 mg).
When administered alone, imipenem is metabolized in the kidneys by dehydropeptidase-I.
Če je imipenem uporabljen sam, se v ledvicah presnovi z dihidropeptidazo-I.
Haematology A positive direct or indirect Coombs test may develop during treatment with imipenem/cilastatin.
Med zdravljenjem z imipenemom/cilastatinom se lahko pojavi pozitiven rezultat neposrednega ali posrednega Coombsovega testa.
Generalized seizures have been reported in patients who received ganciclovir and TIENAM.
Pri bolnikih, ki so prejemali ganciklovir in zdravilo TIENAM, so poročali o generaliziranih napadih krčev.
TIENAM may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.
Zdravilo TIENAM se lahko uporablja za zdravljenje nevtropeničnih bolnikov z zvišano telesno temperaturo, če obstaja sum, da je vzrok zvišane temperature bakterijska okužba.